Back to search

Article

Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization

2026-01-12

Abstract excerpt

Remdesivir (REM) and its parent drug, GS-441524 (GS-44), are used to treat cats with Feline Infectious Peritonitis (FIP), resulting in a survival rate of c 85% (range 77%-96%). Cats suffering from FIP exhibit complex and variable clinical presentations, which will cause concurrent variations in the pharmacokinetics (PK) of GS-44. In turn, this will vary the ability of target cells (monocytes and tissue macrophages...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a7078f54-4053-5eff-9e6d-7f4fe1bffde0
DOI
10.20944/preprints202601.0788.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose OptimizationDOI 10.20944/preprints202601.0788.v1
Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different?Semantic proximity
Fecal Feline Coronavirus RNA Shedding and Spike Gene Mutations in Cats with Feline Infectious Peritonitis Treated with GS-441524.Semantic proximity
Pharmacological Therapy of 141 Client-Owned Cats with Feline Infectious Peritonitis with Mutian ® Xraphconn Adenosine Nucleoside Analogue and Prognostic Prediction of Their Clinical OutcomesSemantic proximity
Surveillance for feline herpesvirus type 1 mutation and development of resistance in cats treated with antiviral medicationsSemantic proximity
A rational approach to identifying effective combined anticoronaviral therapies against feline coronavirusSemantic proximity
Population pharmacokinetic modeling and Monte Carlo simulation-based dosing optimization of trimethoprim-sulfamethoxazole in critically ill patients.Semantic proximity
Population variability in animal health: Influence on dose-exposure-response relationships: Part II: Modelling and simulation.Semantic proximity
Principles and practice of HIV-protease inhibitor pharmacoenhancement.Semantic proximity
Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.Semantic proximity
Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.Semantic proximity
Plasma concentrations of nirmatrelvir and molnupiravir required for inhibition of SARS-CoV-2 replication differ between rhesus macaques and humansSemantic proximity
Title page: Pharmacokinetics of Cefovecin (Convenia®) After 8 mg/kg Intramuscular Administration in Bottlenose Dolphins (Tursiops truncatus): Age-Related DifferencesSemantic proximity
Select a neighboring publication to make it the new centre.